- 48 Downloads
A case series described an 82-year-old man and a 79-year-old man, of whom, the former experienced regression of melanocytic nevi during immunotherapy with pembrolizumab for metastatic melanoma, while the latter experienced regression of melanocytic nevi following immunotherapy with ipilimumab, dabrafenib and trametinib, and during treatment with pembrolizumab for metastatic melanoma [routes not stated; not all dosages and times to reactions onsets clearly stated].
Case 1: An 82-year-old man started receiving pembrolizumab 2 mg/kg [frequency not stated] for metastatic stage-IV BRAF K601E/L584F mutant melanoma. He also underwent stereotactic Gamma Knife radiosurgery. After five cycles (~4 months) of pembrolizumab therapy, he presented with a pink-and-brown macule on his flank, measuring 10mm. Dermoscopic examination revealed a lesion with pigmentation and an unorganised homogeneous reticular pattern with grey dots and a focal blue-grey veil. The findings were negative for blistering...
- Mauzo SH, et al. Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade. International Journal of Dermatology 58: 1045-1052, No. 9, Sep 2019. Available from: URL: http://doi.org/10.1111/ijd.13833 - USACrossRefGoogle Scholar